Summary
Regeneron Pharmaceuticals, Inc. (REGN) announced an important change to its Board of Directors through an 8-K filing on October 3, 2022. The company has elected Craig B. Thompson, M.D. as a new director, expanding the Board from 12 to 13 members. Dr. Thompson's appointment is effective immediately and he will serve until the 2023 Annual Shareholder Meeting. This addition signifies a potential strengthening of the Board's expertise, particularly in technology, as Dr. Thompson has also been appointed to the Board's Technology Committee. Investors should note that Dr. Thompson's compensation will align with the company's existing non-employee director compensation structure, as previously detailed in their proxy statement. There are no disclosed understandings or arrangements with other parties regarding his selection. This move is a governance update that could impact strategic oversight and technological direction for Regeneron.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. appointed Dr. Craig B. Thompson as a new director to its Board of Directors.
- 2The Board of Directors has been expanded from 12 to 13 members.
- 3Dr. Thompson will serve as a director until the 2023 Annual Shareholder Meeting.
- 4Dr. Thompson has been appointed to the Board's Technology Committee.
- 5Dr. Thompson's compensation will follow the company's standard practices for non-employee directors.
- 6There are no undisclosed arrangements or understandings related to Dr. Thompson's appointment.
- 7The filing is an 8-K Current Report, indicating a significant event impacting the company's governance.